Search Results

BioCapital

NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes

NexImmune, Inc. announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.

October 24, 2023

·

5 min read

BioCapital

NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NexImmune, Inc. announced the closing of its previously announced registered direct offering of 304,731 shares of its common stock at a purchase price of $12.05 per share in a registered direct offering priced at-the-market under Nasdaq rules.

February 6, 2024

·

5 min read

BioCapital

NexImmune Announces 1-for-25 Reverse Stock Split

NexImmune, Inc. announced that the Board of Directors and stockholders of the Company approved a 1-for-25 reverse stock split of the Company’s common stock at a special meeting of the Company held on October 17, 2023.

October 18, 2023

·

5 min read

BioCapital

NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting

NexImmune, Inc. today announced that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA, being held November 1-5, 2023.

October 19, 2023

·

4 min read

BioCapital

NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy

NexImmune, Inc. announced that, in order to reduce its cash expenditures while continuing to pursue its existing strategic plan, its Board of Directors approved and its management is implementing an approximately 53% reduction in workforce, designed to reduce costs and extend the Company’s cash.

August 31, 2023

·

4 min read

Business

NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates

NexImmune, Inc. (Nasdaq: NEXI) today reported financial results for the first quarter 2023.

May 15, 2023

·

8 min read

Business

NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates

NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today reported financial results for the second quarter of 2023.

August 10, 2023

·

11 min read

BioCapital

NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting

NexImmune, Inc. (Nasdaq: NEXI) today announced that it will be presenting a poster at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, being held in Boston from June 20-23, 2023.

May 22, 2023

·

4 min read

Business

NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today reported financial results for the fourth quarter and full year 2022.

March 28, 2023

·

11 min read

BioCapital

NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting

NexImmune, Inc. (Nasdaq: NEXI) today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, June 2 – June 6, 2023.

April 26, 2023

·

4 min read